

internation PCT/EP 03/12699

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K39/00 A61K49/16 A61K39/395 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

 $\begin{array}{ll} \mbox{Minimum documentation searched (classification system followed by classification symbols)} \\ \mbox{IPC 7} & \mbox{A61K} \end{array}$

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, MEDLINE, WPI Data, PAJ, CHEM ABS Data

Category •	Citation of document, with Indication, where appropriate, of the relevant passages	Relevant to claim No.
Х	WO 91 03493 A (UNIV SOUTHAMPTON) 21 March 1991 (1991-03-21)	1-6,12, 18,19
Y	the whole document	7-11, 13-17, 20,21
X	EP 0 404 097 A (BEHRINGWERKE AG) 27 December 1990 (1990-12-27) cited in the application	1,2,4-6, 12,18,19
Υ	page 2, line 1 -page 3, line 46; claims 1-11	1-21
X	WO 93 11161 A (ENZON INC) 10 June 1993 (1993-06-10) cited in the application	1-6,12, 18,19
Υ	page 4, line 14 -page 7, line 31; claims 1-18 page 13, line 8 -page 17, line 33	1-21
•		

Further documents are listed in the continuation of box C.	Y Patent lamily members are used in arribex.		
Special categories of cited documents:	*T* later document published after the international filing date		
A document defining the general state of the art which is not considered to be of particular relevance	or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention		
E earlier document but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to		
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another	hyolve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention		
citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or	cannol be considered to involve an inventive step when the document is combined with one or more other such docu-		
other means	ments, such combination being obvious to a person skilled in the art.		
P document published prior to the international filing date but later than the priority date claimed	*&* document member of the same patent family		
Date of the actual completion of the international search	Date of mailing of the international search report		
2 March 2004	11/03/2004		
Name and mailing address of the ISA	Authorized officer		
European Patent Office, P.B. 5818 Patentiaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax. (+31-70) 340-3016	Greif, G		



Internation Application No PCT/EP 03/12699

C.(Continue	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 6 447 776 B1 (BECKER KARL-FRIEDRICH ET AL) 10 September 2002 (2002-09-10) cited in the application column 4, line 66 -column 5, line 67; table 2 column 8, line 46 -column 9, line 58	7,8
Υ	ARTEAGA DE MURPHY C ET AL: "PHOSPHINE REDUCED IGG: A NEW METHOD FOR 99MTC LABELING IMMUNOGLOBULINS" JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY, ARTICLES, ELSEVIER SEQUOIA S.A., LAUSANNE, CH, vol. 220, no. 1, 1997, pages 41-45, XP000199389 the whole document	11,12, 14,17,18
Υ	EP 0 419 203 A (IMMUNOMEDICS INC) 27 March 1991 (1991-03-27) the whole document	11,12, 14,17,18
Υ	YASUSHI FUJIOKA ET AL: "Renal metabolism of 3'-iodohippuryl N-maleoyl -L-Lysine (HML)-conjugated Fab fragments" BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 12, no. 2, March 2001 (2001-03), pages 178-185, XP001165761 ISSN: 1043-1802 abstract; figure 2	12,13
Y	SAVIRANTA PETRI ET AL: "In vitro enzymatic biotinylation of recombinant Fab fragments through a peptide acceptor tail" BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 9, no. 6, November 1998 (1998-11), pages 725-735, XP002159053 ISSN: 1043-1802 the whole document	9,10,20, 21
Y	SENEKOWITSCH-SCHMIDTKE REINGARD ET AL: "Highly specific tumor binding of a 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional alpha-radioimmunotherapy of diffuse-type gastric cancer" CANCER RESEARCH, vol. 61, no. 7, 1 April 2001 (2001-04-01), pages 2804-2808, XP001179836 ISSN: 0008-5472 the whole document	1-7,11, 12,14



Internation pplication No
PCT/EP 03/12699

		101/11 03/12099
	etion) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Category °	Chation of document, with indication, where appropriate, of the relevant years good	
P,Y	MIEDERER MATTHIAS ET AL: "Comparison of the radiotoxicity of two alpha-particle-emitting immunoconjugates, terbium-149 and bismuth-213, directed against a tumor-specific, exon 9 deleted (d9) E-cadherin adhesion protein." RADIATION RESEARCH, vol. 159, no. 5, May 2003 (2003-05), pages 612-620, XP009026798 ISSN: 0033-7587 (ISSN print) the whole document	1-7,11, 12,14
P,Y	HUBER ROSWITHA ET AL: "Locoregional alpha-radioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-specific monoclonal antibody." CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. UNITED STATES 1 SEP 2003, vol. 9, no. 10 Pt 2, 1 September 2003 (2003-09-01), pages 39225-85, XP001179837 ISSN: 1078-0432 the whole document	1-7,11, 12,14
Α	US 5 274 119 A (FRAZIER KEVIN A ET AL) 28 December 1993 (1993-12-28) the whole document	1-21
A	ANELLI ET AL: "L-Glutamic acid and L-lysine as useful building blocks for the preparation of bifunctional DTPA-like ligands" BIOCONJUGATE CHEMISTRY, vol. 10, no. 1, 1999, pages 137-140,ABSTRACT, XP002115959 the whole document	1-21





Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inte	emational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1.	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2. X	Claims Nos.: 1-2,4-6,8-21(all in parts) because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically:
	see FURTHER INFORMATION sheet PCT/ISA/210
3.	Cialms Nos.:
J. [because they are dependent claims and are not drafted in accordance with the second and third sentences of Hule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This int	ernational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this international Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this international Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this international Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Rema	The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-2,4-6,8-21(a)1 in parts)

Present claims 1, 19, 20 and 21 relate to an agent for the diagnosis or treatment of tumors, whereby the part of the agent corresponding to the recognition unit is defined with respect of the characteristics of the tumor. Said definition is so unclear, and thus represents an undue burden in order to determine what tumors fall under said definition, and consequently what the characteristics of the recognition unit should be. As a result, the claims contain so many options, variables, and possible tumor types that a lack of clarity (and/or conciseness) within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claim impossible.

Present claim 2 relates to an extremely large number of possible compounds, namely immunoglobulins or fragments thereof, polypeptides and polysaccharides.

Claims 5 and 6 relate to a great number of possible proteins altered as a result of a variety of a mutation. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Consequently, the search has been carried out for those parts of the application which do appear to be clear (and/or concise), namely those agents recited in the examples, as well as the parts of the agent for the diagnosis or treatment of tumors as defined in claims 3, 7, 8, 12-17.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.



Internation Application No
PCT/EP 03/12699

WO 9103493 A 21-03-1991 AU 6290090 A WO 9103493 A1 EP 0404097 A 27-12-1990 DE 3920358 A1 AT 142230 T AU 639241 B2 AU 5762190 A CA 2019559 A1 DE 59010480 D1 DK 404097 T3 EP 0404097 A2 ES 2093623 T3 GR 3021109 T3 IE 902254 A1 JP 2978210 B2 JP 3048699 A KR 183980 B1	08-04-1991 21-03-1991
AT 142230 T AU 639241 B2 AU 5762190 A CA 2019559 A1 DE 59010480 D1 DK 404097 T3 EP 0404097 A2 ES 2093623 T3 GR 3021109 T3 IE 902254 A1 JP 2978210 B2 JP 3048699 A KR 183980 B1	15-09-1996 22-07-1993 03-01-1991 22-12-1990 10-10-1996 10-02-1997 27-12-1990 01-01-1997 31-12-1996 16-01-1991 15-11-1999
AU 5762190 A CA 2019559 A1 DE 59010480 D1 DK 404097 T3 EP 0404097 A2 ES 2093623 T3 GR 3021109 T3 IE 902254 A1 JP 2978210 B2 JP 3048699 A KR 183980 B1	03-01-1991 22-12-1990 10-10-1996 10-02-1997 27-12-1990 01-01-1997 31-12-1996 16-01-1991 15-11-1999
CA 2019559 A1 DE 59010480 D1 DK 404097 T3 EP 0404097 A2 ES 2093623 T3 GR 3021109 T3 IE 902254 A1 JP 2978210 B2 JP 3048699 A KR 183980 B1	22-12-1990 10-10-1996 10-02-1997 27-12-1990 01-01-1997 31-12-1996 16-01-1991 15-11-1999
DE 59010480 D1 DK 404097 T3 EP 0404097 A2 ES 2093623 T3 GR 3021109 T3 IE 902254 A1 JP 2978210 B2 JP 3048699 A KR 183980 B1	10-10-1996 10-02-1997 27-12-1990 01-01-1997 31-12-1996 16-01-1991 15-11-1999
DK 404097 T3 EP 0404097 A2 ES 2093623 T3 GR 3021109 T3 IE 902254 A1 JP 2978210 B2 JP 3048699 A KR 183980 B1	10-02-1997 27-12-1990 01-01-1997 31-12-1996 16-01-1991 15-11-1999
EP 0404097 A2 ES 2093623 T3 GR 3021109 T3 IE 902254 A1 JP 2978210 B2 JP 3048699 A KR 183980 B1	27-12-1990 01-01-1997 31-12-1996 16-01-1991 15-11-1999
ES 2093623 T3 GR 3021109 T3 IE 902254 A1 JP 2978210 B2 JP 3048699 A KR 183980 B1	01-01-1997 31-12-1996 16-01-1991 15-11-1999
IE 902254 A1 JP 2978210 B2 JP 3048699 A KR 183980 B1	16-01-1991 15-11-1999
JP 2978210 B2 JP 3048699 A KR 183980 B1	15-11-1999
JP 3048699 A KR 183980 B1	
KR 183980 B1	01-07-1441
	01-04-1999
PT 94443 A	
RU 2096459 C1	20-11-1997
US 5591828 A	07-01-1997
WO 9311161 A 10-06-1993 AT 207080 T	15-11-2001
AU 3178993 A	28-06-1993
CA 2122732 A1 DE 69232137 D1	10-06-1993 22-11-2001
DE 69232137 DE 69232137 T2	29-05-2002
DK 617706 T3	12-11-2001
EP 1136556 A1	26-09-2001
EP 0617706 A1	05-10-1994
ES 2165851 T3	01-04-2002
JP 7501451 T WO 9311161 A1	16-02-1995 10-06-1993
US 6027725 A	22-02-2000
US 6121424 A	19-09-2000
US 6025165 A	15-02-2000
US 6103889 A	15-08-2000
US 5869620 A	09-02-1999
US 6515110 B1	· 04-02-2003
US 6447776 B1 10-09-2002 DE 19629938 C1	27-11-1997
EP 0821060 A2 JP 10127283 A	28-01-1998 19-05-1998
US 2003054005 A1	20-03-2003
EP 0419203 A 27-03-1991 AT 110281 T	15-09-1994
AU 640698 B2	02-09-1993
AU 6521490 A	18-04-1991
CA 1340250 C	15-12-1998
DE 69011789 D1 DE 69011789 T2	29-09-1994 15-12-1994
DK 419203 T3	05-12-1994
EP 0419203 A1	27-03-1991
ES 2063286 T3	01-01-1995
FI 921146 A	17-03-1992
IE 903360 A1 IL 95723 A	10-04-1991 31-08-1995
JP 7023326 B	31-08-1995 15-03-1995
JP 4505455 T	24-09-1992







Patent document cited in search report	Publication date		Patent family member(s)	Publication date
EP 0419203	Α	KR	9615611 B1	18-11-1996
		NO	920853 A	04-03-1992
		US	5612016 A	18-03-1997
		WO	9104056 A1	04-04-1991
		US	5601825 A	11-02-1997
•		US	5328679 A	12-07-1994
		US	5541297 A	30-07-1996
		ZA	9007420 A	31-07-1991
US 5274119	A 28-12-1993	NONE	·	